Casebia Therapeutics Begins Operations
The joint venture, created through a collaboration with Bayer and CRISPR Therapeutics, will be based in Cambridge, MA.
On August 19, 2016, Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, started operations in Cambridge, MA. In December 2015, Bayer and CRISPR Therapeutics agreed to create a joint venture to discover, develop, and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. The two parties formally closed the transaction in the first quarter of 2016.
The joint venture has recently been incorporated as Casebia Therapeutics, a United Kingdom entity with its primary base of research operations in Cambridge. Casebia has access to gene-editing technology from CRISPR Therapeutics in specific disease areas, as well as access to protein engineering knowledge and relevant disease information through Bayer.
Source: Bayer
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
